<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin A Raby, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia (CAH). This conversion is mediated by 21-hydroxylase, the enzyme encoded by the
         <em>
          CYP21A2
         </em>
         gene.
        </p>
        <p>
         Patients with "classic," or the most severe form of CAH due to 21-hydroxylase deficiency, present during the neonatal period and early infancy with adrenal insufficiency. "Nonclassic," or late-onset 21-hydroxylase deficiency, presents later in life with signs of androgen excess and without atypical genitalia. Clinical features in childhood may include premature pubarche and accelerated bone age; adolescent and adult females may present with hirsutism, menstrual irregularity, infertility, and acne. Some patients with nonclassic CAH remain asymptomatic.
        </p>
        <p>
         The pathophysiology, genetics, and clinical manifestations of the nonclassic form of CAH due to 21-hydroxylase deficiency are reviewed here. The diagnosis and treatment of nonclassic 21-hydroxylase deficiency and the classic form of CAH due to 21-hydroxylase deficiency are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/147.html" rel="external">
          "Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/145.html" rel="external">
          "Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/136.html" rel="external">
          "Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5800.html" rel="external">
          "Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon neonatal screening studies that detect classic congenital adrenal hyperplasia (CAH), 21-hydroxylase deficiency is a common inherited disorder. The prevalence based upon such studies has been estimated to be approximately 1 in 14,200 live births, ranging from 1 in 28,000 in the Chinese population to 1 in 280 in the Yupik people. (See
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Prevalence'
         </a>
         .)
        </p>
        <p>
         The nonclassic form (late-onset) is one of the most common autosomal recessive diseases, and the frequency is ethnic-specific. Among White individuals, the prevalence of the nonclassic form may be as high as 1 in 1000 to 1 in 100 [
         <a href="#rid1">
          1-3
         </a>
         ], with the prevalence being even higher among Mediterranean, Hispanic, and Eastern European Jewish women [
         <a href="#rid4">
          4,5
         </a>
         ]. Most patients with the nonclassic form will not be identified by the neonatal screening studies, which are based upon detection of very high levels of 17-hydroxyprogesterone [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Women with the nonclassic form typically present with oligomenorrhea and hyperandrogenism and, therefore, may be indistinguishable from polycystic ovary syndrome (PCOS). The prevalence of nonclassic CAH in women who present with apparent PCOS is variable, depending upon the population studied. As an example, in two different regions of Turkey, the prevalence ranged from 9.5 to 66 percent [
         <a href="#rid7">
          7,8
         </a>
         ]. In the United States, the disorder occurs in approximately 1 to 4 percent of White women with clinical evidence of androgen excess [
         <a href="#rid4">
          4,9,10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p>
         The frequency of heterozygote carriers has been reported to be about 1 in 60 to 80 in some studies [
         <a href="#rid1">
          1,11
         </a>
         ], but closer to 1 in 10 in another study using mutation analysis in a European population [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In children who present with premature pubarche (premature development of pubic hair), the prevalence of nonclassic
         <em>
          CYP21A2
         </em>
         deficiency has been reported to be very low [
         <a href="#rid13">
          13
         </a>
         ], or as high as 30 percent, in high-risk ethnic groups [
         <a href="#rid14">
          14
         </a>
         ]. In an unselected population of 31 such patients, none were found to have the disorder [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The prevalence in men with idiopathic oligospermia is not established. However, in one study of Jewish men presenting to an infertility clinic, there were no cases found in either 222 subjects with abnormal semen analysis or a concurrent control group of 262 men with normal semen analysis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol in patients with
         <em>
          CYP21A2
         </em>
         deficiency results in decreased cortisol synthesis and therefore increased corticotropin (ACTH) secretion (
         <a class="graphic graphic_figure graphicRef81907" href="/z/d/graphic/81907.html" rel="external">
          figure 1
         </a>
         ). The resulting adrenal stimulation leads to increased production of androgens. The severity of disease relates to the degree to which the mutations compromise enzyme activity. In patients with the nonclassic form, enzymatic activity is reduced but sufficient to maintain normal glucocorticoid and mineralocorticoid production, at the expense of excessive androgen production.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with the other forms of congenital adrenal hyperplasia (CAH),
         <em>
          CYP21A2
         </em>
         deficiency is transmitted as an autosomal recessive disorder. Humans have two
         <em>
          CYP21A
         </em>
         genes, a non-functional pseudogene (
         <em>
          CYP21A1
         </em>
         or
         <em>
          CYP21P
         </em>
         ) and the active gene (
         <em>
          CYP21A2
         </em>
         or
         <em>
          CYP21
         </em>
         ), both located in a 35-kilobase region of chromosome 6p21.3 within the major histocompatibility locus.
        </p>
        <p>
         The two
         <em>
          CYP21A
         </em>
         genes are more than 90 percent homologous. This high degree of homology facilitates recombination events during meiosis, with consequent exchanges of segments of deoxyribonucleic acid (DNA) between the two genes.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large or unequal cross-over exchanges can result in a large deletion of the active gene, or a non-functioning hybrid gene. Patients who are homozygous or heterozygous for such mutations have classic forms of CAH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The exchange of smaller amounts of material can result in hybrid
         <em>
          CYP21A1
         </em>
         /
         <em>
          CYP21A2
         </em>
         gene products with reduced but not absent enzyme activity. A patient who is heterozygous for this and a typical large gene deletion may have nonclassic
         <em>
          CYP21A2
         </em>
         deficiency [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Genotype versus phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is not always possible to predict the phenotype of these patients from the specific mutation(s) of the
         <em>
          CYP21A2
         </em>
         gene, but there are general correlations between genotype and phenotype. Patients with
         <em>
          CYP21A2
         </em>
         mutations can be divided into groups according to the predicted effect of the mutation on 21-hydroxylase enzymatic activity. (See
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Genotype versus phenotype'
         </a>
         .)
        </p>
        <p>
         Women with the late-onset form may be either compound heterozygotes (with a classic mutation and a variant allele) or homozygotes with two variant alleles, allowing for 20 to 60 percent of normal enzymatic activity (eg, with point mutations leading to conservative amino acid substitutions such as Val281Leu).
        </p>
        <p>
         Women who are compound heterozygotes for two different
         <em>
          CYP21A2
         </em>
         mutations usually have the phenotype associated with the less severe of the two genetic defects [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Obligate heterozygote carriers (with one normal allele) may have mild biochemical abnormalities [
         <a href="#rid19">
          19-21
         </a>
         ], but no clinically important endocrine disorder.
        </p>
        <p>
         Despite these general correlations, the
         <em>
          CYP21A2
         </em>
         deficiency phenotype does not always correlate precisely with the genotype, suggesting that other genes influence the clinical manifestations. (See
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Genotype versus phenotype'
         </a>
         .)
        </p>
        <p>
         Prenatal diagnosis, neonatal screening and genotyping for
         <em>
          CYP21A2
         </em>
         deficiency are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/145.html" rel="external">
          "Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL PRESENTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with nonclassic congenital adrenal hyperplasia (CAH) present after the neonatal period with signs of hyperandrogenism, without adrenal insufficiency. Clinical features may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Premature pubarche. Children with nonclassic
         <em>
          CYP21A2
         </em>
         deficiency typically differ from children with ordinary premature adrenarche in having a bone age advanced more than 2.0 SD for age. (See
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medication-resistant cystic acne [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Accelerated growth with tall stature as children.
        </p>
        <p>
        </p>
        <p>
         However, these children may enter puberty early, with early epiphyseal closure, leading to short stature as an adult, although short stature is not a consistent feature [
         <a href="#rid4">
          4,23,24
         </a>
         ]. The management of children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5800.html" rel="external">
          "Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Female reproduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescent and adult women have acne, hirsutism, and menstrual irregularity that are indistinguishable from polycystic ovary syndrome (PCOS) [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         In one study of 220 females with nonclassic CAH, the clinical presentation varied by the age of the patient [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nearly all patients younger than 10 years presented with premature pubarche; clitoromegaly and acne were less common (20 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presenting clinical features in adolescents and adult women included hirsutism (59 percent), oligomenorrhea (54 percent), acne (33 percent), infertility (13 percent), clitoromegaly (10 percent), alopecia (8 percent), and primary amenorrhea (4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of hirsutism increased significantly with age, from 70 percent in adolescents to 90 percent in 40- to 49-year-old women. When present, the degree of hirsutism was similar at all ages.
        </p>
        <p>
        </p>
        <p>
         The following features may help distinguish nonclassic CAH and PCOS [
         <a href="#rid27">
          27,28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonclassic CAH is uncommon in African-American and Hispanic-Puerto Rican women [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insulin resistance may be more severe, but probably not more common in polycystic ovarian syndrome [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polycystic ovaries on ultrasound are less common in nonclassic CAH (40 versus 70 percent) [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity is more common in women with polycystic ovary disease [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a questionnaire-based study, women with nonclassic CAH show increased masculinization (defeminization) when compared with normal women [
         <a href="#rid31">
          31,32
         </a>
         ]. These attributes were more extreme in women with the classic form of the disease.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Fertility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with the classic form of CAH due to 21-hydroxylase deficiency have low fertility rates that correlate with the severity of the mutation. (See
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Female reproduction'
         </a>
         .)
        </p>
        <p>
         In contrast, subfertility is milder in women with the nonclassic form of 21-hydroxylase deficiency. Many women conceive spontaneously, while others have anovulatory infertility that responds to glucocorticoids alone or combined with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate"
         </a>
         .)
        </p>
        <p>
         However, the risk of spontaneous abortion (SAB) appears to be high in these women compared with normal women (≥25 percent versus 10 to 15 percent, respectively) [
         <a href="#rid26">
          26,35-39
         </a>
         ]. Treatment with glucocorticoids may lower this risk, as illustrated in a study of 85 women with the nonclassic form who were pursuing pregnancy. Women who had received therapy with glucocorticoids in order to conceive (n = 36), had a lower risk of SAB than those who had not received glucocorticoids (n = 49; 6.5 versus 26.3 percent, respectively) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Risk of classic CAH in offspring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with the late-onset form of nonclassic congenital adrenal hyperplasia (CAH) who seek fertility should be aware of the potential risk of giving birth to an infant with classic
         <em>
          CYP21A2
         </em>
         deficiency. Women with the nonclassic disorder who carry at least one allele affected by a severe mutation and whose partner also carries the severe mutation are at risk of having an infant who is homozygous for the severe mutation (ie, classic CAH). This was illustrated in a report of 162 live births in 101 women with the late-onset form [
         <a href="#rid35">
          35
         </a>
         ]. At birth, 4 (2.5 percent) and 24 (15 percent) of the 162 infants were diagnosed with the classic form and the late-onset nonclassic form, respectively.
        </p>
        <p>
         If genetic screening has not been performed by a couple prior to conception, the birth of an affected infant should prompt consideration of genotyping and consideration of prenatal diagnosis in subsequent pregnancies.
        </p>
        <p>
         However, genotyping for
         <em>
          CYP21
         </em>
         mutations is not widely available, usually not covered by insurance, and does not detect all mutations; as a result, recommendations for screening protocols for these couples have not been established [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Prenatal diagnosis, neonatal screening, and genotyping for
         <em>
          CYP21A2
         </em>
         deficiency are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/145.html" rel="external">
          "Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Men
         </span>
         <span class="headingEndMark">
          —
         </span>
         In males, it can be difficult to differentiate between simple virilizing forms of "classic"
         <em>
          CYP21A2
         </em>
         deficiency and "non-classic" forms. Both can present in childhood with premature pubarche or adrenarche and eventual short stature. After puberty, nonclassic men usually present with acne or infertility. Asymptomatic individuals (obligate heterozygote carriers) may be diagnosed because of an affected family member.
        </p>
        <p>
         Boys and men with classic
         <em>
          CYP21A2
         </em>
         deficiency often develop testicular masses (testicular adrenal rest tumors). During adulthood, these are often associated with oligospermia and infertility. Although most men with the nonclassic form are thought to have normal testicular function and normal fertility, some do present with testicular adrenal rests and infertility [
         <a href="#rid23">
          23,41,42
         </a>
         ].
        </p>
        <p>
         In general, treatment is not necessary for men with nonclassic
         <em>
          CYP21A2
         </em>
         deficiency who do not desire future fertility. However, in men with a testicular mass and/or oligospermia, glucocorticoid therapy should be given until fertility is no longer desired [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/145.html" rel="external">
          "Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/136.html" rel="external">
          "Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults", section on 'Fertility'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Adrenal incidentalomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although 60 percent of patients with unilateral adrenal incidentalomas, and even more of those with bilateral incidentalomas, have exaggerated serum 17-hydroxyprogesterone responses to ACTH stimulation [
         <a href="#rid4">
          4
         </a>
         ], the prevalence of germline
         <em>
          CYP21A2
         </em>
         mutations is low. However, unilateral and bilateral adrenal incidentalomas were found in 10 of 12 patients with simple virilizing and five of seven patients with late-onset CAH, as well as 9 of 10 heterozygotic siblings [
         <a href="#rid44">
          44
         </a>
         ]. Most tumors had a diameter of less than 2 cm, but three patients had masses more than 5 cm in size. Adrenal masses in children with
         <em>
          CYP21A2
         </em>
         deficiency are usually benign [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2432391024">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112671.html" rel="external">
          "Society guideline links: Classic and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         –
         <strong>
         </strong>
         Nonclassic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive diseases, and the frequency is ethnic-specific (see
         <a class="local">
          'Prevalence'
         </a>
         above). The genetics of this disorder are discussed above. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
         –
         <strong>
         </strong>
         Children may present with precocious pubarche, medication-resistant acne, and accelerated growth. (See
         <a class="local">
          'Clinical presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adolescent girls
         </strong>
         –
         <strong>
         </strong>
         Adolescent girls typically present with acne, hirsutism, and menstrual irregularity (oligoovulation), features that are indistinguishable from the polycystic ovary syndrome (PCOS). (See
         <a class="local">
          'Female reproduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adult women
         </strong>
         –
         <strong>
         </strong>
         Adult women also present with acne, hirsutism, and menstrual irregularity. In addition, anovulatory infertility is common in women who are untreated. Most conceive with ovulation induction (glucocorticoids alone or combined with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate), and the rate of early pregnancy loss appears to be no higher than normal after treatment begins. (See
         <a class="local">
          'Fertility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Men
         </strong>
         –
         <strong>
         </strong>
         Although most men with the nonclassic form are thought to have normal testicular function and normal fertility, some do present with testicular adrenal rests and infertility. (See
         <a class="local">
          'Clinical presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3795771995">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferenczi A, Garami M, Kiss E, et al. Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84:2369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannah-Shmouni F, Morissette R, Sinaii N, et al. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med 2017; 19:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Votava F, Török D, Kovács J, et al. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. Eur J Endocrinol 2005; 152:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yarman S, Dursun A, Oguz F, Alagol F. The prevalence, molecular analysis and HLA typing of late-onset 21-hydroxylase deficiency in Turkish woman with hirsutism and polycystic ovary. Endocr J 2004; 51:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel N, Tonyukuk V, Emral R, et al. The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia. Endocr J 2003; 50:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmina E, Rosato F, Jannì A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HH, Kuo JM, Chao HT, et al. Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese. J Clin Endocrinol Metab 2000; 85:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumgartner-Parzer SM, Nowotny P, Heinze G, et al. Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 2005; 90:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granoff AB, Chasalow FI, Blethen SL. 17-Hydroxyprogesterone responses to adrenocorticotropin in children with premature adrenarche. J Clin Endocrinol Metab 1985; 60:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temeck JW, Pang SY, Nelson C, New MI. Genetic defects of steroidogenesis in premature pubarche. J Clin Endocrinol Metab 1987; 64:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris AH, Reiter EO, Geffner ME, et al. Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche. J Clin Endocrinol Metab 1989; 69:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinkas H, Fuchs S, Klipper-Aurbach Y, et al. Non-classical 21-hydroxylase deficiency: prevalence in males with unexplained abnormal sperm analysis. Fertil Steril 2010; 93:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           L'Allemand D, Tardy V, Grüters A, et al. How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 2000; 85:4562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lajić S, Clauin S, Robins T, et al. Novel mutations in CYP21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab 2002; 87:2824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witchel SF, Lee PA, Suda-Hartman M, et al. Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997; 82:2097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutai JP, Kowarski AA, Migeon CJ. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 1977; 90:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charmandari E, Merke DP, Negro PJ, et al. Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab 2004; 89:2228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose LI, Newmark SR, Strauss JS, Pochi PE. Adrenocortical hydroxylase deficiencies in acne vulgaris. J Invest Dermatol 1976; 66:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91:4205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron FJ, Tebbutt N, Montalto J, et al. Endocrinology and auxology of sibships with non-classical congenital adrenal hyperplasia. Arch Dis Child 1996; 74:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrousos GP, Loriaux DL, Mann DL, Cutler GB Jr. Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. Ann Intern Med 1982; 96:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stikkelbroeck NM, Hermus AR, Braat DD, Otten BJ. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran C, Azziz R. 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med 2003; 21:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speiser PW, Dupont B, Rubinstein P, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 37:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran C, Azziz R, Carmina E, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000; 183:1468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer-Bahlburg HF, Dolezal C, Baker SW, New MI. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Gender development in women with congenital adrenal hyperplasia as a function of disorder severity. Arch Sex Behav 2006; 35:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birnbaum MD, Rose LI. The partial adrenocortical hydroxylase deficiency syndrome in infertile women. Fertil Steril 1979; 32:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merke DP, Auchus RJ. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. N Engl J Med 2020; 383:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran C, Azziz R, Weintrob N, et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91:3451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman S, Billaud L, Thalabard JC, et al. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 74:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewailly D. Nonclassic 21-hydroxylase deficiency. Semin Reprod Med 2002; 20:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zinaman MJ, Clegg ED, Brown CC, et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Practice Committee of the American Society for Reproductive Medicine. Information on commonly asked questions about genetic evaluation and counseling for infertile couples. Fertil Steril 2004; 82 Suppl 1:S97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrousos GP, Loriaux DL, Sherins RJ, Cutler GB Jr. Unilateral testicular enlargement resulting from inapparent 21-hydroxylase deficiency. J Urol 1981; 126:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiitinen A, Välimäki M. Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. J Clin Endocrinol Metab 2002; 87:2442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002; 136:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 74:685.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 144 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7096533" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A pilot newborn screening for congenital adrenal hyperplasia in Alaska.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10404805" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9521938" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10857554" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28541281" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15941926" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15004406" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The prevalence, molecular analysis and HLA typing of late-onset 21-hydroxylase deficiency in Turkish woman with hirsutism and polycystic ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14709856" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8157702" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical review 56: Nonclassic adrenal hyperplasia: current concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263820" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690861" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572419" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2982895" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : 17-Hydroxyprogesterone responses to adrenocorticotropin in children with premature adrenarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3029158" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Genetic defects of steroidogenesis in premature pubarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2550505" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19200987" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Non-classical 21-hydroxylase deficiency: prevalence in males with unexplained abnormal sperm analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134109" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050257" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Novel mutations in CYP21 detected in individuals with hyperandrogenism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215278" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/192874" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126546" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/178807" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Adrenocortical hydroxylase deficiencies in acne vulgaris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912124" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Extensive clinical experience: nonclassical 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8669955" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Endocrinology and auxology of sibships with non-classical congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6977282" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665708" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14764747" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Androgen excess in women: experience with over 1000 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14593552" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9556656" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : High frequency of nonclassical steroid 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11120512" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18157628" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16902816" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Gender development in women with congenital adrenal hyperplasia as a function of disorder severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/227754" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The partial adrenocortical hydroxylase deficiency syndrome in infertile women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32966723" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16822826" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310999" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12428204" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Nonclassic 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20080854" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8774277" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Estimates of human fertility and pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15363702" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Information on commonly asked questions about genetic evaluation and counseling for infertile couples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6265655" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Unilateral testicular enlargement resulting from inapparent 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050196" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11848730" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1311000" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
